p53-Induced apoptosis and inhibitors of p53

Current Medicinal Chemistry

Volumn 16, Issue 21, 2009, Pages 2627-2640

  Nayak, Surendra Kumar ^a   Panesar, Paramjit Singh ^a   Kumar, Harish ^a  

^a SANT LONGOWAL INSTITUTE OF ENGINEERING AND TECHNOLOGY   (India)

Author keywords

Apoptosis; Diseases; p53 inhibitors; p53 Pathway

Indexed keywords

AMIFOSTINE; APOPTOSIS INHIBITOR; CASPASE 9; IMIDAZOBENZOTHIAZOLE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NOCODAZOLE; P53 INHIBITOR; PIFITHRIN ALPHA; PIFITHRIN BETA; PIFITHRIN DERIVATIVE; PIFITHRIN MU; PROTEIN BAD; PROTEIN BCL 2; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P53; SULFONAMIDE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; CELL PROTECTION; CELL SURVIVAL; CLINICAL TRIAL; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DNA DAMAGE; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSFORMATION; FAMILIAL CANCER; GENE INACTIVATION; HEAD AND NECK CANCER; HEMATOLOGIC DISEASE; HUMAN; KIDNEY DISEASE; LIVER DISEASE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MYELODYSPLASTIC SYNDROME; NEUROPROTECTION; NONHUMAN; OVARY CANCER; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; PROTEIN FUNCTION; RADIATION PROTECTION; REVIEW; SKIN DISEASE; STRUCTURE ACTIVITY RELATION; UTERINE CERVIX CANCER; VIRUS INFECTION;

AMIFOSTINE; APOPTOSIS; AUTOIMMUNE DISEASES; BENZOTHIAZOLES; HUMANS; LI-FRAUMENI SYNDROME; NEURODEGENERATIVE DISEASES; NOCODAZOLE; SIGNAL TRANSDUCTION; SKIN DISEASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70349378533     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788681976     Document Type: Review

References (153)

1. Ucker, D.S. Death by suicide: One-way to go in mammalian cellular development? New Biol., 1991, 3, 103-109.
2. Lu, X.; Lee, M.; Tran, T.; Block, T. High level expression of apoptosis inhibitor in hepatoma cell line expressing Hepatitis B virus. Int. J. Med. Sci., 2005, 2, 30-35.
3. Steller, H.; Grether, M.E. Programmed cell death in Drosophila. Neuron, 1994, 13, 1269-1274.
4. Zeng, X.; Yan, T.; Schupp, J.E.; Seo, Y.; Kinsella, T.J. DNA mismatch repair initiates 6-thioguanine - induced autophagy through p53 activation in human tumor cells. Clin. Cancer Res., 2007, 13, 1315-1321.
5. Kaelin, W.G. Jr. Choosing anticancer drug targets in the postgenomic era. J. Clin. Invest., 1999, 104, 1503-1506.
6. Maguire, T.; Harrison, P.; Hyink, O.; Kalmakoff, J.; Ward, V.K. The inhibitors of apoptosis of Epiphyas postvittana nucleopolyhedrovirus. J. Gen. Virol., 2000, 81, 2803-2811.
7. Talasz, H.; Helliger, W.; Sarg, B.; Debbage, P.L.; Puschendorf, B.; Lindner, H. Hyperphosphorylation of histone H2A.X and dephosphorylation of histone H1 subtypes in the course of apoptosis. Cell Death Differ., 2002, 9, 27-39.
8. Levine, A.J. p53, the cellular gatekeeper for growth and division. Cell, 1997, 88, 323-331.
9. Amundson, S.A.; Myers, T.G.; Fornace, A.J. Jr. Roles for p53 in growth arrest and apoptosis: Putting on the brakes after genotoxic stress. Oncogene, 1998, 17, 3287-3299.
10. Joseph, T.W.; Zaika, A.; Moll, U.M. Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage. FASEB J., 2003, 17, 1622-1630.
11. Mihara, M.; Erster, S.; Zaika, A.; Petrenko, O.; Chittenden, T.; Pancoska, P.; Moll, U.M. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell, 2003, 11, 577-590.
12. Kaspar, A.A.; Okada, S.; Kumar, J.; Poulain, F.R.; Drouvalakis, K.A.; Kelekar, A.; Hanson, D.A.; Kluck, R.M.; Hitoshi, Y.; Johnson, D.E.; Froelich, C.J.; Thompson, C.B.; Newmeyer, D.D.; Anel, A.; Clayberger, C.; Krensky, A.M. A distinct pathway of cell-mediated apoptosis initiated by granulysin. J. Immunol., 2001, 167, 350-356.
13. Webster, K.A.; Bishopric, N.H. Apoptosis inhibitors for heart disease. Circulation, 2003, 108, 2954-2956.
14. Soane, L.; Fiskum, G. J. Bioenerg. Biomembr., 2005, 37, 179.
15. Eeva, J.; Ropponen, A.; Nuutinen, U.; Eeva, S.-T. Matto, M.; Eray, M.; Pelkonen, J. The CD40-induced protection against CD95-mediated apoptosis is associated with a rapid upregulation of anti-apoptotic c-FLIP. Mol. Immunol., 2007, 44, 1230-1237.
16. Chi, S.W.; Lee, S.H.; Kim, D.H.; Ahn, M.J.; Kim, J.S.; Woo, J.Y.; Torizawa, T.; Kainosho, M.; Han, K.H. Structural details on mdm2-p53 interaction. J. Biol. Chem., 2005, 280, 38795-38802.
17. Takimoto, R.; El-Deiry, W.S. DNA replication blockade impairs p53-transactivation. P. Natl. Acad. Sci. USA, 2001, 98, 781-783.
18. Tang, Y.; Zhao, W.; Chen, Y.; Zhao, Y.; Gu, W. Acetylation is indispensable for p53 activation. Cell, 2008, 133, 612-626.
19. Pietrancosta, N.; Moumen, A.; Dono, R.; Lingor, P.; Planchamp, V.; Lamballe, F.; Bahr, M.; Kraus, J.L.; Maina, F. Iminotetrahydro-benzothiazole derivatives as p53 inhibitors: Discovery of a highly potent in vivo inhibitor and its action mechanism. J. Med. Chem., 2006, 49, 3645-3652.
20. Mercer, J.; Mahmoudi, M.; Bennett, M. DNA damage, p53, apoptosis and vascular disease. Mutat. Res., 2007, 621, 75-86
21. Shimabukuro, M.; Zhou, Y.-T.; Levi, M.; Unger, R.H. Fatty acid-induced β cell apoptosis: A link between obesity and diabetes. P. Natl. Acad. Sci. USA, 1998, 95, 2498-2502.
22. Duan, W.; Zhu, X.; La denheim, B.; Yu, Q.S.; Guo, Z.; Oyler, J.; Cutler, R.G.; Cadet, J.L.; Greig, N.H.; Mattson, M.P. p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann. Neurol., 2002, 52, 597-606.
23. Emamaullee, J.A.; Shapiro, A.M. J. Interventional strategies to prevent beta-cell apoptosis in islet transplantation. Diabetes, 2006, 55, 1907-1914.
24. Kim, Y.-M.; Choi, B.-M.; Kim, Y.-S.; Kwon, Y.-G.; Kibbe, M.R.; Billiar, T.R.; Tzeng, E. Protective effect of p53 in vascular smooth muscle cells against nitric oxide-induced apoptosis is mediated by up-regulation of heme oxygenase-2. BMB Rep., 2008, 41, 164-169.
25. Schimmer, A.D. Inhibitor of apoptosis proteins: Translating basic knowledge into clinical practice. Cancer Res., 2004, 64, 7183-7190.
26. Bonni, A.; Brunet, A.; West, A.E.; Datta, S.R.; Takasu, M.A.; Greenberg, M.E. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science, 1999, 286, 1358-1362.
27. Johnstone, R.W.; Lowe, S.W. Apoptosis: A link between cancer genetics and chemotherapy. Cell, 2002, 108, 153-164.
28. Chipuk, J.E.; Kuwana, T.; Bouchier-Hayes, L.; Droin, N.M.; Newmeyer, D.D.; Schuler, M.; Green, D.R. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science, 2004, 303, 1010-1014.
29. Hainaut, P.; Hollstein, M. p53 and human cancer: The first ten thousand mutations. Adv. Cancer Res., 2000, 77, 81-137.
30. Oren, M. Regulation of the p53 tumor suppressor protein. J. Biol. Chem., 1999, 274, 36031-36034.
31. Vousden, K.H.; Lu, X. Live or let die: The cell's response to p53. Nat. Rev. Cancer, 2002, 2, 594-604.
32. Hoffman, W.H.; Biade, S.; Zilfou, J.T.; Chen, J.; Murphy, M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem., 2002, 277, 3247-3257
33. Brooks, C.L.; Gu, W. p53 ubiquitination: Mdm2 and beyond. Mol. Cell, 2006, 21, 307-315.
34. Shangary, S.; Wang, S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: A novel approach for cancer therapy. Ann. Rev. Pharmacol. Toxicol., 2009, 49, 223-241.
35. Szak, S.T.; Mays D.; Pietenpol, J.A. Kinetics of p53 binding to promoter sites in vivo. Mol. Cell. Biol., 2001, 21, 3375-3386.
36. Higashitsuji, H.; Higashitsuji, H.; Itoh, K.; Sakurai, T.; Nagao, T.; Sumitomo, H.; Masuda, T.; Dawson, S.; Shimada, Y.; Mayer, R.J.; Fujita, J. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell, 2005, 8, 75-87.
37. Colaluca, I.N.; Tosoni, D.; Nuciforo, P.; Senic-Matuglia, F.; Galimberti, V.; Viale, G.; Pece, S.; Di Fiore, P.P. NUMB controls p53 tumour suppressor activity. Nature, 2008, 451, 76-80.
38. Henriksson, M.; Selivanova, G.; Lindstrom, M.; Wiman, K.G. Inactivation of Myc-induced p53-dependent apoptosis in human tumors. Apoptosis, 2001, 6, 133-137.
39. Haupt, S.; Berger, M.; Goldberg, Z.; Haupt, Y. Apoptosis - the p53 network. J. Cell Sci., 2003, 116, 4077-4085.
40. Eischen, C.M.; Weber, J.D.; Roussel, M.F.; Sherr, C.J.; Cleveland, J.L. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Gene Dev., 1999, 13, 2658- 669.
41. Harada, H.; Andersen, J.S.; Mann, M.; Terada, N.; Korsmeyer, S.J. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. P. Natl. Acad. Sci. USA, 2001, 98, 9666-9670.
42. Mayo, L.D.; Donner, D.B. The PTEN, Mdm2, p53 tumor suppressoroncoprotein network. Trends Biochem. Sci., 2002, 27, 462-467
43. Appella, E. Modulation of p53 function in cellular regulation. Eur. J. Biochem., 2001, 268, 2763-2764.
44. Herr, I.; Ucur, E.; Herzer, K.; Okouoyo, S.; Ridder, R.; Krammer, P.H.; von Knebel Doeberitz, M.; Debatin, K.M. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res., 2003, 63, 3112-3120.
45. Komarov, P.G.; Komarova, E.A.; Kondratov, R.V.; Christov-Tselkov, K.; Coon, J.S.; Chernov, M.V.; Gudkov, A.V. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science, 1999, 285, 1733-1737.
46. Leker, R.R.; Ahronowiz, M.; Greig, N.H.; Ovadia, H. The role of p53-induced apoptosis in cerebral ischemia: Effects of the p53 inhibitor pifithrin alpha. Exp. Neurol., 2004, 187, 487-486
47. Endo, H.; Kamada, H.; Nito, C.; Nishi, T.; Chan, P.H. Mitochondrial translocation of p53 mediates release of cytochrome c and hippocampal CA1 neuronal death after transient global cerebral ischemia in rats. J. Neurosci., 2006, 26, 7974-7983.
48. Culmsee, C.; Zhu, X.; Yu, Q.S.; Chan, S.L.; amandola, S.; Guo, Z.; Greig, N.H.; Mattson, M.P. A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. J. Neurochem., 2001, 77, 220-228
49. Komarova, E.A.; Neznanov, N.; Komarov, P.G.; Chernov, M.V.; Wang, K.; Gudkov, A.V. p53 inhibitor pifithrin alpha can suppress heat shock and glucocorticoid signaling pathways. J. Biol. Chem., 2003, 278, 15465-15468.
50. Barchechath, S.D.; Tawatao, R.I.; Corr, M.; Carson, D.A.; Cottam, H.B. Inhibitors of apoptosis in lymphocytes: Synthesis and biological evaluation of compounds related to pifithrin-alpha. J. Med. Chem., 2005, 48, 6409-6422.
51. Zhu, X.; Yu, Q.-S.; Culter, R.G.; Culmsee, C.W.; Holloway, H.W.; Lahiri, D.K.; Mattson, M.P.; Greig, N.H. Interdependence between physical parameters and selection of substituent groups for correlation studies. J. Med. Chem., 1971, 14, 680-684.
52. Gary, R.K.; Jensen, D.A. The p53 inhibitor pifithrin-alpha forms a sparingly soluble derivative via intramolecular cyclization under physiological conditions. Mol. Pharmaceutics, 2005, 2, 462-474.
53. Walton, M.I.; Wilson, S.C.; Hardcastle, I.R.; Mirza, A.R.; Workman, P. An evaluation of the ability of pifithrin-alpha and -beta to inhibit p53 function in two wild-type p53 human tumor cell lines. Mol. Cancer Ther., 2005, 4, 1369-1377.
54. Johnson, M.; Lajiness, M.; Maggiora, G. Molecular similarity: A basis for designing drug screening programs. Prog. Clin. Biol. Res., 1989, 291, 167-171.
55. Evans, B.E.; Rittle, K.E.; Bock, M.G.; DiPardo, R.M.; Freidinger, R.M.; Whitter, W.L.; Lundell, G.F.; Veber, D.F.; Anderson, P.S.; Chang, R.S.L.; Lotti, V.J.; Cerino, D.J.; Chen, T.B.;Kling, P.J.;Kunkel, K.A.; Springer, J.P.; Hirshfield, J. Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem., 1988, 31, 2235-2246.
56. Pietrancosta, N.; Maina, F.; Dono, R.; Moumen, A.; Garino, C.; Laras, Y.; Burlet, S.; Quelever, G.; Kraus, J.L. Novel cyclized Pifithrin-alpha p53 inactivators: Synthesis and biological studies. Bioorg. Med. Chem. Lett., 2005, 15, 1561-1564.
57. Erster, S.; Mihara, M.; Kim, R.H.; Petrenko, O.; Moll, U.M. In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol. Cell Biol., 2004, 24, 6728-6741
58. Smith, M.L.; Seo, Y.R. p53 regulation of DNA excision repair pathways. Mutagenesis, 2002, 17, 149-156.
59. Strom, E.; Sathe, S.; Kamarov, P.G.; Chernova, O.B.; Pavlovska, I.; Shyshynova, I.; Bosykh, D.A.; Burdelya, L.G.; Macklis, R.M.; Skaliter, R.; Komarowa, E.A.;Gudkov, A.V. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat. Chem. Biol., 2004, 2, 474-479.
60. Gudkov, A.V.; Komarova, E.A. Dangerous habits of a security guard: The two faces of p53 as a drug target. Hum. Mol. Genet., 2007, 16, R67-R72.
61. Sathe, S.E.; Komarov, P.G.; Chernova, O.B.; Pavlovska, I.; Shyshynova, I.; Bosykh, D.A.; Burdelya, L.G.; Macklis, R.M.; Skaliter, R.; Komarova, E.A.; Gudkov, A.V. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat. Chem. Biol., 2006, 2, 474-479.
62. Zhang, H.; Shi, X.; Zhang, Q.-J.; Hampong, M.; Harry Paddon, H.; Wahyuningsih, D.; Pelech, S. Nocodazole-induced p53-dependent c-Jun N-terminal kinase activation reduces apoptosis in human colon carcinoma HCT116 cells. J. Biol. Chem., 2002, 277, 43648-43658.
63. Sayed, M.; Pelech, S.L.; Wong, C.; Marotta, A.; Salh, B. Protein kinase CK2 is involved in G2 arrest and apoptosis following spindle damage in epithelial cells. Oncogene, 2001, 20, 6994-7005
64. Capizzi, R.L. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol). Eur. J. Cancer, 1996, 32A, S5-S16.
65. Acosta, J.C.; Richard, C.; Delgado, M.D.; Horita, M.; Rizzo, M.G.; Fernandez-Luna, J.L.; Leon, J. Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells. Mol. Cancer Ther., 2003, 2, 893-900.
66. McEvoy, G.K. Editor. AHFS 2002 Drug Information. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc.; 2002.
67. Links, M.; Lewis, C. Chemoprotectants: A review of their clinical pharmacology and therapeutic efficacy. Drugs, 1999, 57, 293308.
68. Green, D.R.; Kroemer, G. Pharmacological manipulation of cell death: clinical applications in sight? J. Clin. Invest., 2005, 115, 2610-2617.
69. Li, B.; Yang, J.; Tao, M.; Nayini, J.; Horvath, E.; Chopra, H.; Meyer, P.; Venugopal, P.; Preisler, H.D. Poor prognosis acute myelogenous leukemia 2 - biological and molecular biological characteristics and treatment outcome. Leukemia Res., 2000, 24, 777-789.
70. Preisler, H.D.; Li, B.; Yang, B.L.; Huang, R.W.; Devemy, E.; Venugopal, P.; Tao, M.; Chopra, H.; Gregory, S.A.; Adler, S.; Sivaraman, S.; Toofanfard, P.; Jajeh, A.; Galvez, A.; Robin, E. Suppression of telomerase activity and cytokine messenger RNA levels in acute myelogenous leukemia cells in vivo in patients by amifostine and interleukin 4. Clin. Cancer Res., 2000, 6, 807-812.
71. Cagnoni, P.J.; Jones, R.B.; Bearman, S.I.; Ross, M.; Hami, L.; Franklin, W.A.; Capizzi, R.; Schein, P.S.; Shpall, E.J. Use of amifostine in bone marrow purging. Semin. Oncol., 1996, 23, 44-48.
72. List, A.F.; Heaton, R.; Glinsmann-Gibson, B.; Capizzi, R.L. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Semin. Oncol., 1996, 23, 58-63.
73. List, A.F. Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia. Semin. Oncol., 1999, 26, 61-67.
74. List, A.F.; Heaton, R.; Glinsmann-Gibson, B.; Capizzi, R.L. Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors. Leukemia, 1998, 12, 1596-1602.
75. List, A.F.; Brasfield, F.; Heaton, R.; Glinsmann-Gibson, B.; Crook, L.; Taetle, R.; Capizzi, R.L. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood, 1997, 90, 3364-3369.
76. Amifostine. USP DI. Drug information for the health care professional. 20th Ed, Englewood, Colorado: Micromedex, Inc.; 2002, Vol. 1.
77. Qin, H.; Yu, T.; Qing, T.; Liu, Y.; Zhao, Y.; Cai, J.; Li, J.; Song, Z.; Qu, X.; Zhou, P.; Wu, J.; Ding, M.; Deng, H. Regulation of apoptosis and differentiation by p53 in human embryonic stem cells. J. Biol. Chem., 2007, 282, 5842-5852.
78. Nagata, S. Apoptosis: Telling cells their time is up. Curr. Biol., 1996, 6, 1241-1243.
79. Campisi, J. Fragile fugue: P53 in aging, cancer and IGF signaling. Nat. Med., 2004, 10, 231-232.
80. Lynette, M.; Lu, X.; Nader, G.; Stuart, T.; Lawrence A.D. Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity. Mech. ageing dev., 2007, 128, 717-730.
81. Sedarous, M.; Keramaris, E.; O'Hare, M.; Melloni, E.; Slack, R.S.; Elce, J.S.; Greer, P.A.; Park, D.S. Calpains mediate p53 activation and neuronal death evoked by DNA damage. J. Biol. Chem., 2003, 278, 26031-26038.
82. Castedo, M.; Ferri, K.F.; Blanco, J.; Roumier, T.; Larochette, N.; Barretina, J.; Amendola, A.; Nardacci, R.; Metivier, D.; Este, J.A.; Piacentini, M.; Kroemer, G. Human immunodeficiency virus 1 envelope glycoprotein complex-induced apoptosis involves mammalian target of rapamycin/FKBP12-rapamycin-associated protein-mediated p53 phosphorylation. J. Exp. Med., 2001, 194, 1097-1110.
83. Cui, R.; Widlund, H.R.; Feige, E.; Lin, J.Y.; Wilensky, D.L.; Igras, V.E.; D'Orazio, J.; Fung, C.Y.; Schanbacher, C.F.; Granter, S.R.; Fisher, D.E. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell, 2007, 128, 853-864.
84. Artal-Sanz, M.; Tavernarakis, N. Proteolytic mechanisms in necrotic cell death and neurodegeneration. FEBS Lett., 2005, 579, 3287-3296.
85. Gibson, R.M. Does apoptosis have a role in neurodegeneration? BMJ, 2001, 322, 1539-1540.
86. de la Monte, S.M.; Sohn, Y.K.; Wands, J.R. Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease. J. Neurol. Sci., 1997, 152, 73-83.
87. Blum, D.; Wu, Y.; Nissou, M.F. Arnaud, S.; Benabid, A.-L.; Verna, J.M. p53 and Bax activation in 6-hydroxydopamine-induced apoptosis in PC12 cells. Brain Res., 1997, 751, 139.
88. Crumrine, R.C.; Thomas, A.L.; Morgan, P.F. Attenuation of p53 expression protects against focal ischemic damage in transgenic mice. J. Cerebr. Blood Flow Metab., 1994, 14, 887-891.
89. Napieralski, J.A.; Raghupathi, R.; McIntosh, T.K. The tumor-suppressor gene, p53, is induced in injured brain regions following experimental traumatic brain injury. Mol. Brain Res., 1999, 71, 78-86.
90. Cregan, S.P.; MacLaurin, J.G.; Craig, C.G.; Robertson, G.S.; Nicholson, D.W.; Park, D.S.; Slack, R.S. Bax-dependent caspase-3 activation is a key determinant in p53-induced apoptosis in neurons. J. Neurosci., 1999, 19, 7860-7869.
91. Sakhi, S.; Bruce, A.; Sun, N. Tocco G, Baudry, M.; Schreiber, S.S. Induction of tumor suppressor p53 and DNA fragmentation in organotypic hippocampal cultures following excitotoxin treatment. Exp. Neurol., 1997, 145, 81-88.
92. Morrison, R.S.; Wenzel, H.J.; Kinoshita, Y. Robbins, C.A.; Donehower, L.A.; Schwartzkroin, P.A. Loss of the p53 tumor suppressor gene protects neurons from kainate-induced cell death. J. Neurosci., 1996, 16, 1337-1345.
93. Trimmer, P.A.; Smith, T.S.; Jung, A.B.; Bennett, J.P. Jr. Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity. Neurodegeneration, 1996, 5, 233-239.
94. Hirata, H.; Cadet, J.L. p53-knockout mice are protected against the long-term effects of methamphetamine on dopaminergic terminals and cell bodies. J. Neurochem., 1997, 69, 780-790.
95. Williams G.T.; Smith, C.A.; Spooncer, E.; Dexter T.M.; Taylor, D.R. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature, 1990, 343, 76-79
96. Koury, M.J.; Bondurant, M.C. Erythropoietin retards DNA break-down and prevents programmed death in erythroid progenitor cells. Science, 1990, 248, 378-381.
97. Manabe, A.; Coustan-Smith, E.; Behm, F.G.; Raimondi, S.C.; Campana, D. Blood, 1992, 79, 2370.
98. Yoshida, Y. Hypothesis: Apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia, 1993, 7, 144-146.
99. Clark, D.M.; Lampert, I.A. Apoptosis is a Common Histopathological Finding in Myelodysplasia: The Correlate of Ineffective Haematopoiesis. Leukemia Lymphoma, 1990, 2, 415-418.
100. Yuan, J.; Angelucci, E.; Lucarelli, G. Aljurf, M.; Snyder, L.M.; Kiefer, C.R.; Ma, L.; Schrier, S.L.. Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe beta-thalassemia (Cooley's anemia). Blood, 1993, 82, 374-377.
101. Solary, E.; Bettaieb, A.; Dubrez-Daloz, L.; Corcos, L. Mitochondria as a target for inducing death of malignant hematopoietic cells. Leukemia Lymphoma, 2003, 44, 563-564.
102. Hussein M.R.; Al-Badaiwy, Z.H.; Guirguis, M.N. Analysis of p53 and bcl-2 protein expression in the non-tumorigenic, pretumorigenic, and tumorigenic keratinocytic hyperproliferative lesions. J. Cutan. Pathol., 2004, 31, 643-651.
103. Technau-Ihling, K., Ihling, C.; Kromeier, J.; Brandner, G. Influenza A virus infection of mice induces nuclear accumulation of the tumorsuppressor protein p53 in the lung. Arch. Virol., 2001, 146, 1655-1666.
104. Turpin, E.; Luke, K.; Jones, J.; Tumpey, T.; Konan, K.; Schultz-Cherry, S. Influenza virus infection increases p53 activity: Role of p53 in cell death and viral replication. J. Virol., 2005, 79, 8802-8811.
105. Dubaniewicz, A.; Trzonkowski, P.; Dubaniewicz-Wybieralska, M.; Dubaniewicz, A.; Singh, M.; Mysliwski, A. Comparative analysis of mycobacterial heat shock proteins-induced apoptosis of peripheral blood mononuclear cells in sarcoidosis and tuberculosis. J. Clin. Immunol., 2006, 26, 243-250.
106. Reefman, E.; Limberg, P.C.; Kallenberg, C.G.M.; Bijl, M. Apoptosis in human skin: Role in pathogenesis of various diseases and relevance for therapy. Ann. N. Y. Acad. Sci., 2005, 1051, 52-63
107. Morgan, M.B.; Rose, P. An investigation of apoptosis in androgenetic alopecia. Ann. Clin. Lab. Sci., 2003, 33, 107-112
108. van de Kerkhof, P. Textbook of psoriasis, 2nd Ed., Blackwell Publishing Ltd., Oxford, 2003, pp. 83-109.
109. Bishop, J.M. Molecular themes in oncogenesis. Cell, 1991, 64, 235-248.
110. Marshall, C.J. Tumor suppressor genes. Cell, 1991, 64, 313-326.
111. Tadini, G.; Cerri, A.; Crosti, L. Cattoretti, G.; Berti, E. P53 and oncogenes expression in psoriasis. Acta Derm. Venereol. Suppl., 1989, 146, 33-35.
112. Helander, S.D.; Peters, M.S.; Pittelkow, M.R. Expression of p53 protein in benign and malignant epidermal pathologic conditions. J. Am. Acad. Dermatol., 1993, 29, 741-748.
113. Soini, Y.; Kamel, D.; Paakko, P.; Lehto, V.P.; Oikarinen, A.; Vahakangas, K.V. Aberrant accumulation of p53 associates with Ki67 and mitotic count in benign skin lesions. Br. J. Dermatol., 1994, 131, 514-520.
114. Hannuksela-Svahn, A.; Paakko, P.; Autio, P.; Reunala, T.; Karvonen, J.; Vähäkangas, K. Expression of p53 protein before and after PUVA treatment in psoriasis. Acta Derm. Venereol., 1999, 79, 195-199.
115. Baran, W.; Szepietowski, J.C.; Szybejko-Machaj, G. Expression of p53 protein in psoriasis. Acta dermatoven APA, 2005, 14, 79-83.
116. Ameisen, J.C. From cell activation to cell depletion. The programmed cell death hypothesis of AIDS pathogenesis. Adv. Exp. Med. Biol., 1995, 374, 139-163.
117. Chamond, R.R.; Anon, J.C.; Aguilar, C.M.; Pasadas, F.G. Apoptosis and disease. Alergol. Immunol. Clin., 1999, 14, 367-374.
118. Ishimaru, N.; Arakaki, R.; Omotehara, F.; Yamada, K.; Mishima, K.; Saito, I.; Hayashi, Y. Novel role for RbAp48 in tissue-specific, estrogen deficiency-dependent apoptosis in the exocrine glands. Mol. Cell Biol., 2006, 26, 2924-2935.
119. Casciola-Rosen, L.A.; Anhalt, G.; rosen, A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J. Exp. Med., 1994, 179, 1317-1330.
120. Li, F.P.; Fraumeni, J.F. Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann. Intern. Med., 1969, 71, 747-752.
121. Malkin, D.; Li, F.P.; Strong, L.C.; Fraumeni, J.F. Jr.; Nelson, C.E.; Kim DH, Kassel, J.; Gryka, M.A.; Bischoff, F.Z.; Tainsky, M.A. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science, 1990, 250, 1233- 238.
122. Hisada, M.; Garber, J.E.; Fung, C.Y.; Fraumeni, J.F. Jr.; Li, F.P. Multiple primary cancers in families with Li-Fraumeni syndrome. J. Natl. Cancer Inst., 1998, 90, 606-611.
123. Varley, J.M.; McGown, G.; Thorncroft, M.; Santibanez-Koref, M.F.; Kelsey, A.M.; Tricker, K.J. Evans, D.G.; Birch, J.M. Germline mutations of TP53 in Li-Fraumeni families: An extended study of 39 families. Cancer Res., 1997, 57, 3245-3252.
124. Roth, J.A. Adenovirus p53 gene therapy. Expert Opin. Biol. Ther., 2006, 6, 55-61.
125. Nutting, C.; Camplejohn, R.S.; Gilchrist, R.; Tait, D.; Blake, P.; Knee, G.; Yao, W.Q.; Ross, G.; Fisher, C.; Eeles, R. A patient with 17 primary tumours and a germ line mutation in TP53: Tumour induction by adjuvant therapy? Clin. Oncol. (R Coll Radiol), 2000, 12, 300-304.
126. Limacher, J.M.; Frebourg, T.; Natarajan-Ame, S.; Bergerat, J.P. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int. J. Cancer, 2001, 96, 238-242.
127. Hwang, S.J.; Lozano, G.; Amos, C.I.; Strong, L.C. Germline p53 mutations in a cohort with childhood sarcoma: Sex differences in cancer risk. Am. J. Hum. Genet., 2003, 72, 975-983.
128. Frederickson, R.M.; Carter, B.J.; Pilaro, A.M. Nonclinical toxicology in support of licensure of gene therapies. Mol. Ther., 2003, 8, 8-10.
129. Senzer, N.; Nemunaitis, J.; Nemunaitis, M.; Lamont, J.; Gore, M.; Gabra, H.; Eeles, R.; Sodha, N.; Lynch, F.J.; Zumstein, L.A.; Menander, K.B.; Sobol, R.E.; Chada, S. p53 therapy in a patient with Li-Fraumeni syndrome. Mol. Cancer Ther., 2007, 6, 1478- 482.
130. Woo, D. Apoptosis and loss of renal tissue in polycystic kidney diseases. New Engl. J. Med., 1995, 333, 18-25.
131. Guicciardi, M.E.; Gores, G.J. Apoptosis: A mechanism of acute and chronic liver injury. Gut, 2005, 54, 1024-1033
132. Goldin, R.D.; Hunt, N.C.; Clark, J.; Wickramassinghe, S.N. Apoptotic bodies in a murine model of alcoholic liver disease: Reversibility of ethanol-induced changes. J. Pathol., 1993, 171, 73-76.
133. Gottlieb, R.A.; Burleson, K.O.; Kloner, R.A.; Babior, B.M.; Engler, R.L. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J. Clin. Invest., 1994, 94, 1621-1628.
134. Mercer, J.; Bennett, M. The role of p53 in atherosclerosis. Cell Cycle, 2006, 5, 1907-1909.
135. Whyte, M.K.B.; Meagher, L.C.; MacDermot, J.; Haslett, C. Impairment of function in aging neutrophils is associated with apoptosis. J. Immunol., 1993, 150, 5124-5134.
136. Lockshin, R.A.; Zackeri, Z.F. Programmed cell death: New thoughts and relevance to aging. J. Gerontol., 1990, 45, 135-140.
137. Zuco, V.; Zunino, F. Cyclic pifithrin-α sensitizes wild type p53 tumor cells to antimicrotubule agent-induced apoptosis. Neoplasia, 2008, 10, 587-596.
138. Miyawaki, E.; Lyons, K.; Pahwa, R. Motor complications of chronic levodopa therapy in Parkinson's disease. Clin. Neuropharmacol., 1997, 20, 523-530.
139. Lemke, T.L., Williams, D.A., Roche, V.F., Zito, S.W. In Foye's principles of medicinal chemistry, Booth R.G., 6th Ed.; Wolters Kluwer India Pvt. Ltd., New Delhi, 2008, pp. 679-697.
140. Smith, M.L.; Fornace, A.J.J. Genomic instability and the role of p53 mutations in cancer cells. Curr Opin Oncol., 1995, 7, 69-75.
141. Lowe, S.W.; Ruley, H.E.; Jacks, T.; Housman, D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 1993, 74, 957-967.
142. Bunz, F.; Hwang, P.M.; Torrance, C.; Waldman, T.; Zhang, Y.; Dillehay, L.; Williams, J.; Lengauer, C.; Kinzler, K.W.; Vegelstein, B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest., 1999, 104, 263-269.
143. Barak, Y.; Juven, T.; Haffner, R.; Oren, M. Mdm2 expression is induced by wild-type p53 activity. EMBO J., 1993, 12, 461-468.
144. Momand, J.; Zambetti, G.P.; Olson, D.C.; George, D.; Levine, A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 1992, 69, 1237-1245.
145. Zauberman, A.; Barak, Y.; Ragimov, N.; Levy, N.; Oren, M. Sequence-specific DNA binding by p53: Identification of target sites and lack of binding to p53-MDM2 complexes. EMBO J., 1993, 12, 2799-2808.
146. Haupt, Y.; Maya, R.; Kazaz, A.; Oren, M. Mdm2 promotes the rapid degradation of p53. Nature, 1997, 387, 296-299
147. Kubbutat, M.H.G.; Jones, S.N.; Vousden, K.H. Regulation of p53 stability by Mdm2. Nature, 1997, 387, 299-303.
148. zur Hausen, H. Papillomavirus infections: A major cause of human cancers. Biochim. Biophys. Acta, 1996, 1288, F55-F78.
149. Mietz, J.A.; Unger, T.; Huibregtse, J.M.; Howley, P.M. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J., 1992, 11, 5013-5020.
150. Scheffner, M.; Werness, B.A.; Huibregtse, J.M.; Levine, A.J.; Howley, P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 1990, 63, 1129-1136.
151. Truant, R.; Antunovic, J.; Greenblatt, J.; Prives, C.; Cromlish, J.A. Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. J. Virol., 1995, 69, 1851-1859.
152. Ueda, H.; Ullrich, S.J.; Gangemi, J.D.; Kappel, C.A.; Ngo, L.; Feitelson, M.A. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat. Genet., 1995, 9, 41-47.
153. Cromlish, J.A. Hepatitis B virus-induced hepatocellular carcinoma: possible roles for HBx. Trends Microbiol., 1996, 4, 270-274.